Supernus Pharma released FY2025 Semi-Annual earnings on August 5 After-Market EST, actual revenue USD 315.28 M, actual EPS USD 0.1907

Brief Summary

Supernus Pharmaceuticals reported its 2025 semi-annual financial results, achieving a total revenue of $315.28 million and a net profit of $10.67 million, resulting in an earnings per share (EPS) of $0.1907.

Impact of The News

1. Financial Performance and Market Context